샌프란시스코 베이지역과 인천 송도 바이오클러스터 기업 성장 역량 비교연구
A Comparative Study of Growth Strategies of Bio-cluster Companies in San Francisco and Incheon
Firms of San Francisco Bay bio-clusters have been faced with a rapid decrease in the number of patented medicines and price reduction due to the mass production of bio-similars by other companies including Samsung Biologics or Celtrion at Songdo. San Francisco Bay Area bio-firms have had no choice but to respond in kind. Faced with mass production of bio-similars by Celtrion and SamsungBioespis which are located at the Korean Incheon Songdo bio-cluster, Amgen, a global top bio company of the of the Bay Area bio-cluster has cut the price of it's bio-similars as well as of it's original bio-products. For now and near future, bio-companies at Bay Area and Songdo will lead together the enormous global bio-similar market. But, in the far distant future, bio-companies at Bay Area will have to compete with almost all major bio-companies, major pharmaceutical companies and non pharmaceutical companies such as even Fujiflim Co. which had had nothing to do with bio-industry. So, Bay Area bio-companies including Amgen will have a great difficulty in retrieving the operating profit losses. On the contrary, it is certain for the bio-companies of Songdo bio-cluster will have a good chance to take another leap at the global bio-similar market for considerable time being.
원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.
- 이 논문과 함께 이용한 콘텐츠